Symbiomix Therapeutics

The company's landmark achievement was the development and regulatory approval of its lead product, Solosec™ (secnidazole). This potent, next-generation 5-nitroimidazole antibiotic was formulated as oral granules, representing the first and only single-dose oral treatment for bacterial vaginosis (BV) in adult women. Bacterial vaginosis is the most common gynecological infection in the U.S., affecting an estimated 21 million women annually. The single-dose regimen of Solosec™ was a key benefit, designed to improve patient adherence compared to previous treatments that required multiple daily doses for a week. The FDA designated Solosec™ as a Qualified Infectious Disease Product (QIDP) and granted it Fast Track designation, which provided at least 10 years of market exclusivity.

Symbiomix's business model was centered on the research, development, and subsequent commercialization of this novel therapeutic. The company's revenue stream was predicated on the sales of Solosec™ to the pharmaceutical market. After successfully navigating the clinical trial process, Symbiomix achieved a major milestone in September 2017 when the U.S. Food and Drug Administration (FDA) approved Solosec™. This approval culminated in the company's acquisition by Lupin Inc., the U.S. subsidiary of the global pharmaceutical company Lupin Limited, in October 2017 for a cash consideration of $150 million. The acquisition integrated Solosec™ into Lupin's expanding women's health specialty business.